AstraZeneca-Moderna’s AZD8601 VEGF-A mRNA...

Heart failure (HF), also referred to as Congestive Heart failure (CHF), is a condition in which the heart muscle fails to pump blood as efficiently as it should. This causes an accumulation of blood and fluid in the lungs, resulting in shortness of breath. Certain heart conditions, such as narrowed arteries in the ...

Amber Implants VCFix® spinal system obtains US FDA Breakthrough designation  On October 05, 2021, the US Food and Drug Administration (FDA) granted the Breakthrough Device Designation to VCFix® spinal system, a next-generation spinal implant for spinal injuries developed by Amber Implants, a Netherlands-bas...

Nutraceuticals often referred to as phytochemicals or functional food, are a group of products used both as nutrition for general well-being or as a medicine to control symptoms. These products are helpful in maintaining body growth, improving health, delaying the aging process, physiological balance,  increas...

Myocardial infarction is an irreversible death of heart muscles. It is pathologically referred to as myocardial cell death due to a prolonged lack of oxygen supply (ischemia). The condition is accompanied by chest pain that may appear as a sensation of tightness or pressure initially attributable to diminished cell...

Roche’s Genentech taps Adaptimmune for T-Cell Therapy Collaboration for USD 3 Billion A collaboration valued more than USD 3 billion, Genentech, a member of the Roche Group, declared it will collaborate with Adaptimmune for developing and commercializing allogeneic T-cell therapies to treat multiple cancer indic...

FDA awards Breakthrough Device Designation to Impella ECP  On August 18, 2021, Abiomed received breakthrough device designation from the United States Food and Drug Administration (FDA) for its Impella ECP expandable percutaneous heart pump, the world’s smallest heart pump and the first to be compatible wit...